...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cardiac failure >Clinical pharmacy services in heart failure: An opinion paper from the heart failure society of america and american college of clinical pharmacy cardiology practice and research network
【24h】

Clinical pharmacy services in heart failure: An opinion paper from the heart failure society of america and american college of clinical pharmacy cardiology practice and research network

机译：心力衰竭的临床药学服务：来自美国心力衰竭学会和美国临床药学心脏病学实践与研究网络学院的意见书

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Heart failure (HF) care takes place in multiple settings, with a variety of providers, and generally involves patients who have multiple comorbidities. This situation is a "perfect storm" of factors that predispose patients to medication errors. Methods and Results: The goals of this paper are to outline potential roles for clinical pharmacists in a multidisciplinary HF team, to document outcomes associated with interventions by clinical pharmacists, to recommend minimum training for clinical pharmacists engaged in HF care, and to suggest financial strategies to support clinical pharmacy services within a multidisciplinary team. As patients transition from inpatient to outpatient settings and between multiple caregivers, pharmacists can positively affect medication reconciliation and education, assure consistency in management that results in improvements in patient satisfaction and medication adherence, and reduce medication errors. For mechanical circulatory support and heart transplant teams, the Centers for Medicare and Medicaid Services considers the participation of a transplant pharmacology expert (e.g., clinical pharmacist) to be a requirement for accreditation, given the highly specialized and complex drug regimens used. Although reports of outcomes from pharmacist interventions have been mixed owing to differences in study design, benefits such as increased use of evidence-based therapies, decreases in HF hospitalizations and emergency department visits, and decreases in all-cause readmissions have been demonstrated. Clinical pharmacists participating in HF or heart transplant teams should have completed specialized postdoctoral training in the form of residencies and/or fellowships in cardiovascular and/or transplant pharmacotherapy, and board certification is recommended. Financial mechanisms to support pharmacist participation in the HF teams are variable. Conclusions: Positive outcomes associated with clinical pharmacist activities support the value of making this resource available to HF teams.
机译：背景：心力衰竭（HF）护理是在多种情况下进行的，提供方多种多样，通常涉及患有多种合并症的患者。这种情况是使患者容易出现用药错误的因素的“完美风暴”。方法和结果：本文的目的是概述多学科HF团队中临床药剂师的潜在作用，记录与临床药剂师干预相关的结果，为从事HF护理的临床药剂师提供最低限度的培训，并建议财务策略在多学科团队中支持临床药学服务。随着患者从住院到门诊过渡以及在多位护理人员之间过渡，药剂师可以积极影响药物和解和教育，确保管理的一致性，从而改善患者的满意度和依从性，并减少用药错误。对于机械循环支持和心脏移植团队，鉴于所使用的高度专业化和复杂的药物治疗方案，医疗保险和医疗补助服务中心将移植药理学专家（例如，临床药剂师）的参与视为认证的要求。尽管由于研究设计的不同，药剂师干预的结果报告也混杂在一起，但已证明了诸如增加使用循证疗法，减少HF住院和急诊就诊以及减少全因再入院等好处。参加HF或心脏移植团队的临床药剂师应以心血管疾病和/或移植药物治疗的住院医师和/或研究金的形式，完成专门的博士后培训，并建议获得董事会认证。支持药剂师参与HF团队的财务机制是可变的。结论：与临床药剂师活动相关的积极成果支持了将这种资源提供给HF团队的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号